CLAL MSX S.A.

NewCo News Biokine Gets $1.2M to Kick Off Phase I/II Trial with CXCR4 Drug.
BIOWORLD Today; 3/18/2009; 1085 words; ...Israel -- brings Biokine's fundraising total to slightly...provided by the company's founders and the Weizmann...as Series A funding from Clal Biotechnology Industries...myeloma and non-Hodgkin's lymphoma patients. (See...trial with CXCR4 inhibitor MSX-122. But Peled explained...

FIMALAC: 2004 Results - Strong Growth in Operating Income.
Business Wire; 3/14/2005; 877 words; ...RESULTS In analyzing Fimalac's results, account should be...December 2003 divestment of CLAL-MSX. In addition, the 2004 figures...the divestments of LBC and CLAL-MSX and the fall in the...the improvement in Facom's operating margin and the continued...

Fimalac: Revenues for the First Nine Months of 2004 up 3.9% Like-for-Like.
Business Wire; 10/25/2004; 518 words; PARIS -- Fimalac's (OTC:FMLCF) (BOURSE...to the deconsolidation of CLAL-MSX and LBC, which were divested...Fitch's revenues for the nine-month...reflecting the company's robust third quarter performance...

Fimalac: First-Half 2004 Results.
Business Wire; 10/7/2004; 701 words; PARIS -- Fimalac's (OTC:FMLCF)(BOURSE...of LBC in early May and of CLAL-MSX at year-end 2003, as well...the divestment of LBC and CLAL-MSX and to the impact of...reflects the impact of Facom's turnaround program underway...

Fimalac: First-Half 2004 Sales: Up 3.7% Like-for-Like.
Business Wire; 7/28/2004; 480 words; ...sales were down 7.8%, due mainly to the exclusion of CLAL-MSX and LBC, which were divested in December 2003 and May 2004...Beissbarth sales rose 9.5%* to EUR 81.0 million. Cassina's sales came to EUR 58.6 million, down by a modest 1...